Human papillomavirus vaccine introduction in Vietnam: formative research findings

Nghi, Nguyen Quy; LaMontagne, D. Scott; Bingham, Allison; Rafiq, Mirriam; Phuong, Le Thi; Liên, Nguyễn Thị Kim; Khanh, Nguyễn Công; Hong, Duong Thi; Huyen, Dang Thi Thanh; Tho, Nguyen Thi Thi; Hiển, Nguyễn Trần

doi:10.1071/sh09123

Cited by 30 publications

(28 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In formative research conducted prior to the implementation of HPV vaccinations in these communities in Vietnam, researchers noted a general lack of knowledge and awareness about the existence of HPV vaccine and its use to prevent cervical cancer (Nghi et al, 2010). However, our survey found most mothers and daughters had heard of HPV vaccine and knew what it could prevent.…”

Section: 2587 Knowledge Of Cervical Cancer and Hpv Vaccine Post-vaccmentioning

confidence: 70%

“…Prior to HPV vaccine delivery in the demonstration sites in Vietnam, formative research in these areas (Nghi et al, 2010) DOI:http://dx.doi.org/10.7314/APJCP.2012.13.6 Young et al, 2010;Charakorn et al, 2011). Our study investigated knowledge levels of daughters and their mothers who were exposed to HPV vaccine messaging as part of the communication strategy of a vaccination program, exploring the relationship between knowledge of mothers and their respective daughters.…”

Section: Discussionmentioning

confidence: 99%

“…Prior to initiating an HPV vaccination program, assessing the levels of knowledge and awareness in a community has been suggested as a means to develop appropriate educational materials for vaccine recipients and decision-makers (Bingham et al, 2009;Jacob et al, 2010). A number of studies in Vietnam and other Asian countries have reported low levels of knowledge about cervical cancer, HPV, and HPV vaccines (Loi & Nhung, 2004;Dinh et al, 2007;Nghi et al, 2010;Young et al, 2010;Charakorn et al, 2011). These and other HPV vaccine acceptability studies have assessed knowledge and vaccine intentions before HPV vaccine availability (Allen et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Knowledge of Cervical Cancer and HPV Vaccine Post-Vaccination among Mothers and Daughters in Vietnam

Paul¹,

LaMontagne²,

Nt³

2012

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

Background: Limited human papillomavirus (HPV) related knowledge might be a barrier to future vaccine acceptance. From 2008-2010, PATH conducted an HPV vaccination demonstration project in partnership with the government immunization program in Vietnam, which included awareness campaigns prior to vaccination. Objective: To assess and compare knowledge and attitudes about cervical cancer and HPV vaccines between mothers and daughters, and whether knowledge was associated with vaccination status. Methods: We analyzed HPV-related knowledge and attitude data from mother-daughter paired responses to a cross-sectional household survey. After parents completed the survey, daughters were asked the same questions. We calculated the frequency of responses for each question and devised a scaled composite measure for knowledge. Results: Participants believed they had received enough information about cervical cancer and HPV vaccines and it was sufficient to make a decision about vaccination. Fifty percent of the participants knew HPV causes cervical cancer and 80% knew the HPV vaccine prevented cervical cancer. Mothers had more knowledge about cervical cancer and HPV infection (p<0.01), compared to daughters, who had more vaccine specific knowledge (p<0.01). However, the total mean knowledge score was similar for the groups. Girls not fully vaccinated had a lower mean knowledge score than fully vaccinated girls (p<0.001). Conclusions: Our results suggest that the purpose of the HPV vaccine was clearly messaged; however, some misconceptions about cervical cancer and HPV still exist. Limited knowledge about the magnitude of cervical cancer, HPV as a cause of cervical cancer, and HPV vaccines may have contributed to incomplete vaccination.

show abstract

Section: 2587 Knowledge Of Cervical Cancer and Hpv Vaccine Post-vaccmentioning

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Knowledge of Cervical Cancer and HPV Vaccine Post-Vaccination among Mothers and Daughters in Vietnam

Paul¹,

LaMontagne²,

Nt³

2012

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

show abstract

“…Forty‐five articles (full text or abstracts, as indicated in the references) were considered relevant for the recommendations 23, 24, 25, 26, 27, 28, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84. Additionally, EU reviews of the communication about 2009/10 (H1N1) pandemic influenza vaccines 22, 85 and key publications on medicines/vaccines communication were extracted 9, 21, 86, 87, 88, 89.…”

Section: Search Strategymentioning

confidence: 99%

Listen to the public and fulfil their information interests – translating vaccine communication research findings into guidance for regulators

Bahri¹,

Melero²

2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

Regulatory authorities have a crucial role in communicating about the vaccines they license. In terms of content and timing, their communication to the public is usually driven by data on quality, safety and efficacy. However, concerns over safety and vaccine hesitancy have emerged in some communities in various countries, and this demands a new approach to communication, starting with listening to the public debate. Reviewing communication research findings, coming in particular from the cognitive, decision‐making and media sciences, constitutes one mechanism of listening and has led the European Union (EU) regulatory network to developing guidance about which common concerns and information needs of the public to address through proactive and prepared communication. The guidance has been welcomed by EU and international fora. The current article summarizes the recommendations and shares the underlying research findings, as well as a proof of concept that communication research can be valuable for regulators. It is critical that regulators integrate the communication process with product risk assessment in the framework of pharmacovigilance, to ensure that public concerns are addressed in the assessments and that information about evidence and uncertainty relating to safety is provided to the public and vaccination policy makers in a specific, clear and accurate manner. Additionally, information from regulatory authorities should support healthcare professionals in their communication with patients. Meeting the information interests of the public is the principal prerequisite for informed decisions as well as safe and effective use of vaccines and medicines overall. This is also fundamental for trust in the authorities' commitment to patient and population health.

show abstract

“…11 More affordable vaccines are not only required if we are to move to HPV vaccine programs that include both males and females, but are also required in order to deliver HPV vaccines now to women in developing countries, who need them most. Feasibility work, such as that reported in this issue by Nghi et al, 12 indicate that it is realistic to develop programs for preadolescent girls in developing country populations, despite the potential difficulties in accessing and delivering three doses of vaccine to this group. Whilst vaccine delivery globally would be greatly facilitated if fewer than three doses were required for adequate protection, as noted by McIntyre 13 , determining whether a two dose schedule is adequate is a current and important research question.…”

mentioning

confidence: 99%

Closing editorial: processes, opportunities and challenges after introduction of human papillomavirus vaccine

et al. 2010

View full text Add to dashboard Cite

This issue of Sexual Health has reflected on processes, opportunities and challenges that human papillomavirus (HPV) vaccines have created for the prevention of cervical cancer and other HPV-related diseases. Having been in development for over a decade, it is notable how rapidly HPV vaccines have been implemented in developed countries worldwide after registration for use. It is fair to note that this reflects a wave of enthusiasm for a preventive strategy for cervical cancer which, unlike cervical cytology screening, does not rely solely on the use of a test that many women find awkward and which requires an enormous sustained, and often unfeasible, commitment to quality and resources in all steps of the screening process.There are substantial challenges in moving forward: at least with the current generation of prophylactic HPV vaccines, cervical screening programs remain necessary to detect cervical HPV and related lesions due to HPV types not covered by vaccination or which were present at the time of vaccination in catch up cohorts. Close monitoring of participation in cytology screening is required, as is further work investigating the strong potential, and acceptability of, screening using primary HPV DNA testing as a more sensitive way to check, among both vaccinated and unvaccinated women, whether oncogenic HPV infection is currently present at the cervix as a predictor of pre-neoplastic lesions. 1 This approach will allow, in combination with cytological assessment of HPV positive women and perhaps the use of other biomarkers of the potential for progression, a stratification of the future risk of cervical cancer and appropriate management.Australia is in a unique position to observe potentially rapid changes in the epidemiology of HPV infection and disease following the implementation of the National HPV Vaccination Program, which has achieved high coverage in a large section of the female population (aged 12-26 years) over a short time frame. 2 While the speed at which the program was implemented created perhaps unprecedented challenges for success (including political, logistic and communication challenges [3][4][5][6] ), the substantial vaccination coverage achieved is notable. More work is now needed to maintain and improve coverage in the ongoing school programs, through a sustained commitment to education around the complex messages that need to be conveyed about HPV, continuing responsiveness to community concerns about vaccination safety as they arise and through careful examination of coverage data to allow identification of communities where coverage is lower. The National HPV Vaccination Program Register (NHPVR) will facilitate these latter evaluations and is also needed to facilitate evaluation of the impact of the vaccine on Pap screening behaviour and disease incidence. The Register was established with a clear intent that the vaccination data held on the register would be linked with Pap screening data to assess vaccine effectiveness. Logistically the next steps are to develop the syst...

show abstract

Human papillomavirus vaccine introduction in Vietnam: formative research findings

Abstract: Our findings provide options for potential vaccine delivery strategies, appropriate communication strategies and targeted advocacy strategies to introduce HPV vaccines in the Vietnamese context.

Cited by 30 publications

References 15 publications

Knowledge of Cervical Cancer and HPV Vaccine Post-Vaccination among Mothers and Daughters in Vietnam

Knowledge of Cervical Cancer and HPV Vaccine Post-Vaccination among Mothers and Daughters in Vietnam

Listen to the public and fulfil their information interests – translating vaccine communication research findings into guidance for regulators

Closing editorial: processes, opportunities and challenges after introduction of human papillomavirus vaccine

Contact Info

Product

Resources

About